Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HIV drug resistance.

× No keyword cloud information.

19 in total

1. Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors: Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191

Review 2. Resistance to human immunodeficiency virus type 1 protease inhibitors.

Authors: D Boden; M Markowitz
Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191

3. Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.

Authors: Liyu Chen; Zhujun Ao; Kallesh Danappa Jayappa; Gary Kobinger; Shuiping Liu; Guojun Wu; Mark A Wainberg; Xiaojian Yao
Journal: Antimicrob Agents Chemother Date: 2013-05-13 Impact factor: 5.191

4. Ab initio molecular dynamics studies on HIV-1 reverse transcriptase triphosphate binding site: implications for nucleoside-analog drug resistance.

Authors: F Alber; P Carloni
Journal: Protein Sci Date: 2000-12 Impact factor: 6.725

5. Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC).

Authors: Dennis C Liotta; George R Painter
Journal: Acc Chem Res Date: 2016-10-05 Impact factor: 22.384

6. Human recombinant antibody fragments neutralizing human immunodeficiency virus type 1 reverse transcriptase provide an experimental basis for the structural classification of the DNA polymerase family.

Authors: N Gargano; S Biocca; A Bradbury; A Cattaneo
Journal: J Virol Date: 1996-11 Impact factor: 5.103

Review 7. A defective HIV-1 vector for gene transfer to human lymphocytes.

Authors: C Parolin; J Sodroski
Journal: J Mol Med (Berl) Date: 1995-06 Impact factor: 4.599

8. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Authors: K Uberla; C Stahl-Hennig; D Böttiger; K Mätz-Rensing; F J Kaup; J Li; W A Haseltine; B Fleckenstein; G Hunsmann; B Oberg
Journal: Proc Natl Acad Sci U S A Date: 1995-08-29 Impact factor: 11.205

9. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.

Authors: A H Kaplan; S F Michael; R S Wehbie; M F Knigge; D A Paul; L Everitt; D J Kempf; D W Norbeck; J W Erickson; R Swanstrom
Journal: Proc Natl Acad Sci U S A Date: 1994-06-07 Impact factor: 11.205

10. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity.

Authors: R C Jackson
Journal: J Pharmacokinet Biopharm Date: 1997-12